Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. CCHGY
10. PRY:IM

Go back to Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH
(NASDAQ: STRO) Delayed: 30.43 +0.19 (0.63%)
Previous Close $30.24    52 Week High $ 
Open $30.58    52 Week Low $ 
Day High $32.12    P/E N/A 
Day Low $30.13    EPS $ 
Volume 524,927